Expression Of ERCC6L In Prostate Cancer And Its Effect On The Proliferation And Metastasis Of Prostate Cancer

Objective: To analyze the expression of ERCC6L in prostate cancer based on bioinformatics and to explore its effect on prostate proliferation and metastasis in a prostate cancer PC3 cell.Methods: Firstly,the data of 33 tumors in TCGA were downloaded from UCSC database to analyze the expression of ERCC6L gene at pan-cancer level and its correlation with different clinical stages,progression-free survival,and cell cycle alterations in prostate cancer.the expression of ERCC6L in prostate cancer was retrieved from HPA database.The protein expression level of ERCC6L in normal prostate cells(RWPE-1)and prostate cancer cells(LNCaP,PC3,DU145)was then verified by WB assay.Then PC3 cell line was selected to construct knockdown ERCC6L prostate cancer cell line,and the relationship between ERCC6L and cell cycle protein kinase was verified by flow cytometry to detect the change of proliferative activity,CCK8 to detect the change of cell cycle,Transwell assay and scratch assay to detect the change of invasive metastatic ability,and WB assay.Results: Pan-cancer analysis of the TCGA database revealed that ERCC6L was overexpressed in a variety of tumors including prostate cancer and was significantly associated with clinical stage,progression-free survival,cell cycle alterations and CDK2/6 cycle proteins in prostate cancer.high expression of ERCC6L in prostate cancer was also found in the HPA database.The results of WB experiments at the cellular level showed that ERCC6L was overexpressed to varying degrees in prostate cancer cell lines,with the highest expression in PC3 cell lines;flow cytometric assays showed that prostate cancer PC3 cells were significantly blocked in G2/M phase after silencing ERCC6L.Transwell assay and scratch assay showed that the invasive metastatic ability of prostate cancer PC3 cells was significantly reduced after ERCC6L silencing.Conclusion:1.ERCC6L was overexpressed in prostate cancer and significantly correlated with clinical stage,progression-free survival,and alteration of tumor cell cycle in prostate cancer.2.Knockdown of ERCC6L was able to inhibit the proliferation and metastatic ability of prostate cancer PC3 cells.3.ERCC6L may play a role as a pro-oncogene in prostate cancer,providing a potential target for targeted therapy of prostate cancer.